Clinical implications of the mechanism of epidermal growth factor receptor inhibitors
作者： John Marshall
DOI: 10.1002/CNCR.22133
关键词: Pancreatic cancer 、 Medicine 、 Colorectal cancer 、 Cancer research 、 Erlotinib 、 Epidermal growth factor receptor 、 Gefitinib 、 Pharmacology 、 Drug 、 Growth factor receptor 、 Cetuximab 、 Oncology
摘要: Novel therapeutic agents that target the epidermal growth factor receptor (EGFR) constitute an important addition to armamentarium for treatment of metastatic disease. EGFR-targeted currently approved by U.S. Food and Drug Administration include cetuximab, a monoclonal antibody colorectal cancer; small-molecule EGFR tyrosine kinase inhibitor (TKI) erlotinib nonsmall cell lung cancer (NSCLC) pancreatic cancer. Approval TKI gefitinib NSCLC recently was withdrawn. Although both classes anti-EGFR same receptor, substantial distinctions regarding their mechanism significantly affect dosing requirements, toxicity profiles, use as combination agents.
sci-hub.se 参考文章(91)
H Mellstedt, Monoclonal antibodies in human cancer. Drugs of Today. ,vol. 39, pp. 1- 16 ,(2003)
Y Yarden, The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. European Journal of Cancer. ,vol. 37, pp. 3- 8 ,(2001) , 10.1016/S0959-8049(01)00230-1
K Donelan, C M DesRoches, C Schoen, Inadequate health insurance: costs and consequences. MedGenMed : Medscape general medicine. ,vol. 2, ,(2000)
Jonathan M. Bock, Shyh-Min Huang, Paul M. Harari, Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Research. ,vol. 59, pp. 1935- 1940 ,(1999)
W E Miller, H S Earp, N Raab-Traub, The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. Journal of Virology. ,vol. 69, pp. 4390- 4398 ,(1995) , 10.1128/JVI.69.7.4390-4398.1995
Tony DeBlasio, Zhen Fan, Yang Lu, Ding Peng, John Mendelsohn, Howard Scher, Howard Scher, Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Research. ,vol. 56, pp. 3666- 3669 ,(1996)
Mark G. Kris, Howard I. Scher, Vincent A. Miller, Maureen F. Zakowski, Francis M. Sirotnak, Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase Clinical Cancer Research. ,vol. 6, pp. 4885- 4892 ,(2000)
Vincent A. Pollack, Catherine DiOrio, April Theleman, Elsa G. Barbacci, Leslie R. Pustilnik, Mark Neveu, Mikel P. Moyer, Kenneth K. Iwata, Lee Arnold, Michael J. Morin, James D. Moyer, Bruce Boman, Penny Miller, Ann Cunningham, Margaret M. Reynolds, Don Sloan, Jonathan Doty, Induction of Apoptosis and Cell Cycle Arrest by CP-358,774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase Cancer Research. ,vol. 57, pp. 4838- 4848 ,(1997)
J. A. Bonner, P. M. Harari, J. Giralt, J. Baselga, D. Shin, R. Cohen, J. Jassem, N. Azarnia, P. Molloy, K. K. Ang, Improved preservation of larynx with the addition of cetuximab to radiation for cancers of the larynx and hypopharynx Journal of Clinical Oncology. ,vol. 23, pp. 5533- 5533 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.5533
W.K. (Bill) Evans, Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer Cancer Treatment Reviews. ,vol. 30, pp. 655- 659 ,(2004) , 10.1016/J.CTRV.2004.08.002